Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing P...

Published on February 2, 2023

This report describes how a bivalent mRNA booster dose provided additional protection against symptomatic XBB/XBB.1.5 infection for at least the first 3 months after vaccination in persons who had previously received 2-4 monovalent vaccine doses.

Continue reading on website
Other news

EARLY RELEASE: Information for Persons Who Are Immunocompromised Regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages - United States, January 2023

January 27, 2023
This report describes measures that people who are immunocompromised can take to prevent and treat COVID-19.

EARLY RELEASE: Vital Signs: Health Disparities in Hemodialysis-Associated Staphylococcus aureus Bloodstream Infections - United States, 2017-2020

February 6, 2023
This report describes how race, ethnicity, and socioeconomic factors affected hemodialysis-associated S. aureus bloodstream infections.